BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jordan TL, Maar K, Redhage KR, Misra P, Blancas-Mejia LM, Dick CJ, Wall JS, Williams A, Dietz AB, van Wijnen AJ, Lin Y, Ramirez-Alvarado M. Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia 2020;34:1383-93. [PMID: 31796914 DOI: 10.1038/s41375-019-0640-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Martinez-rivas G, Bender S, Sirac C. Understanding AL amyloidosis with a little help from in vivo models. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1008449] [Reference Citation Analysis]
2 Wang Q, Jiang D, Ye Q, Zhou W, Ma J, Wang C, Geng Z, Chu M, Zheng J, Chen H, Huang J, Dai H, Zhang Y, She Z, Fu N, Qiu X. A widely expressed free immunoglobulin κ chain with a unique Vκ4-1/Jκ3 pattern promotes colon cancer invasion and metastasis by activating the integrin β1/FAK pathway. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215720] [Reference Citation Analysis]
3 Del Pozo-yauner L, Turbat-herrera EA, Pérez-carreón JI, Herrera GA. From the Light Chain Sequence to the Tissue Microenvironment: Contribution of the Mesangial Cells to Glomerular Amyloidosis. Hemato 2022;3:232-267. [DOI: 10.3390/hemato3010019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lavatelli F. Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis. Hemato 2022;3:47-62. [DOI: 10.3390/hemato3010005] [Reference Citation Analysis]
5 Wiltshire TD, Deeds MC, Radel DJ, Bornschlegl AM, Schmidt CS, Thebiay JM, Pelleymounter LL, Jacob EK, Stubbs JR, Gastineau DA, Dietz AB. Management of externally manufactured cell therapy products: the Mayo Clinic approach. Cytotherapy 2022;24:19-26. [PMID: 34980364 DOI: 10.1016/j.jcyt.2020.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gatt ME, Pick M. Learning from Patients: The Interplay between Clinical and Laboratory Research in AL Amyloidosis. Hemato 2021;3:3-16. [DOI: 10.3390/hemato3010002] [Reference Citation Analysis]
7 Saito Y, Nakamura K, Ito H. Molecular Mechanisms of Cardiac Amyloidosis. Int J Mol Sci 2021;23:25. [PMID: 35008444 DOI: 10.3390/ijms23010025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Palmiero G, Rubino M, Monda E, Caiazza M, D'Urso L, Carlomagno G, Verrillo F, Ascione R, Manganelli F, Cerciello G, De Rimini ML, Bossone E, Pacileo G, Calabrò P, Golino P, Ascione L, Caso P, Limongelli G. Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis. J Cardiovasc Echogr 2021;31:157-64. [PMID: 34900551 DOI: 10.4103/jcecho.jcecho_16_21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Rognoni P, Mazzini G, Caminito S, Palladini G, Lavatelli F. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Medicina (Kaunas) 2021;57:916. [PMID: 34577839 DOI: 10.3390/medicina57090916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kourelis TV, Dasari SS, Dispenzieri A, Maleszewski JJ, Redfield MM, Fayyaz AU, Grogan M, Ramirez-Alvarado M, Abou Ezzeddine OF, McPhail ED. A Proteomic Atlas of Cardiac Amyloid Plaques. JACC CardioOncol 2020;2:632-43. [PMID: 33511353 DOI: 10.1016/j.jaccao.2020.08.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]